Ascent Solar surges after reaching cell production efficiency benchmark

Tuesday, 12 September 2023, 21:51:16
No summary available.
— Seeking Alpha

Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday”s Mid-Day Session

Tuesday, 12 September 2023, 19:44:01
Gainers Tenon Medical, Inc. (NASDAQ: TNON ) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock. Avalo Therapeutics, Inc. (NASDAQ: AVTX ) gained 52.6% to $0.1295 after the company agreed to divest AVTX-800 series. Shengfeng Development Limited (NASDAQ: SFWL ) rose 45.3% to $13.53. Cognyte Software Ltd. (NASDAQ: CGNT ) gained 24.8% to $5.77 after the company reported better-than-expected second-quarter financial results and issued FY24 guidance above estimates Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA ) gained 24% to $0.4210. Xos, Inc. (NASDAQ: XOS ) gained 23% to $0.3836. Xos was awarded contract by State of California to provide electric step vans to state and local agencies. The Beauty Health Company (NASDAQ: SKIN ) jumped 16.6% to $6.38 after the company announced business transformation program to drive profitability and growth. The company’s board authorized a $100 million share repurchase.
— Benzinga

Is American Battery Technology Company (ABML) Stock Really Up 1,300%?

Tuesday, 12 September 2023, 16:08:22
American Battery Technology Company (OTCMKTS: ABML ) stock surprised investors on Tuesday morning when it appeared to rocketing more than 1,300% higher. However, today’s stock movement is simply the result of the battery materials company’s shares undergoing a reverse split . American Battery Technology Company’s Board of Directors approved a one-for-15 reverse stock split as part of an effort to boost the price of its shares. American Battery Technology Company used this reverse stock split to prepare for a switch of exchanges. The company is moving away from its listing on the OTCQX Markets in favor of a listing on the Nasdaq Capital Market . What This Means For ABML Stock With all of this news and movement, it comes as no surprise that shares of ABML stock are seeing heavy trading on Tuesday. As of this writing, more than 228,000 shares of the company’s stock have changed hands. That’s already well above its daily average trading volume of about 95,000 shares. American Battery Technology Company is a battery materials company focused on supplying battery metals.
— InvestorPlace

Why Is Datasea (DTSS) Stock Down 39% Today?

Tuesday, 12 September 2023, 15:37:06
Datasea (NASDAQ: DTSS ) stock is falling on Tuesday after the smart security solutions company announced a proposed public stock offering . Datasea is offering 5 million shares of DTSS stock at a price of 40 cents per share. That has the company expecting to raise up to $2 million from the offering. There’s also an option for underwriter EF Hutton to acquire another 750,000 shares at the public offering price. Datasea notes that it already has plans for the funds it will raise from this public stock offering. The company says it will use the money to cover costs connected to research and development, market development, as well as for general corporate purposes. How This Affects DTSS Stock Shares of DTSS are falling and that makes sense as investors typically react negatively to public stock offerings. That due to its increasing the total number of shares available, which dilutes current investors’ states. The offering is also priced below the prior closing price of 65 cents. With today’s stock offering news comes heavy trading of DTSS stock.
— InvestorPlace

Why Is Acelyrin (SLRN) Stock Down 58% Today?

Tuesday, 12 September 2023, 15:00:00
Acelyrin (NASDAQ: SLRN ) stock is falling hard on Tuesday after the biopharma company announced clinical trial results . That bad news for investors in SLRN stock comes from the company’s Part B of a Phase 2b/3 trial evaluating izokibep. The company was testing the effectiveness of izokibep as a treatment for moderate-to-severe HS. Unfortunately for Acelyrin, the clinical trial failed its primary endpoint of statistical significance after 16 weeks. That’s despite positive response rates for izokibep and no evidence of safety or tolerability limitations. Shao-Lee Lin, MD, PhD, founder and CEO of Acelyrin, said the following about these clinical trial results. “The consistent and early achievement of HiSCR100, along with our prior izokibep experience in Psoriatic Arthritis, continues to demonstrate the potential of izokibep for resolution of disease, especially in difficult to treat tissues.” How This Affects SLRN Stock Today SLRN stock falling today makes sense when you consider the company’s poor clinical trial results.
— InvestorPlace